8-K: Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Tenax Therapeutics announces its Q1 2025 financial results and provides an update on the Phase 3 LEVEL study of TNX-103 in PH-HFpEF, targeting enrollment completion around year-end 2025 and topline data in mid-2026, while also planning to initiate a second Phase 3 study, LEVEL-2, this year.

Summary

• Tenax Therapeutics reported its financial results for the first quarter ended March 31, 2025.
• The company is progressing with the Phase 3 LEVEL study of TNX-103 for PH-HFpEF and plans to start the LEVEL-2 study in 2025.
• Patient enrollment in the LEVEL study is ongoing, with completion targeted around the end of 2025, expecting to enroll 230 patients.
• Topline data from the LEVEL study is expected in the middle of 2026.
• The company had $111.4 million in cash and cash equivalents as of March 31, 2025, which is expected to fund operations through 2027.
• R&D expenses for Q1 2025 were $5.7 million, up from $2.7 million in Q1 2024, due to increased costs associated with the LEVEL study.
• G&A expenses for Q1 2025 were $5.7 million, compared to $1.2 million in Q1 2024, primarily due to increased compensation and professional fees.
• The net loss for Q1 2025 was $10.4 million, compared to a net loss of $3.8 million for Q1 2024.
• In March 2025, the Company raised approximately $25 million in gross proceeds from a private placement financing.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company is progressing with its clinical trials and has a strong cash position, the increased net loss and G&A expenses are concerning.

Positives

• Tenax has a strong cash position of $111.4 million, expected to fund operations through 2027.
• The company is making progress with the Phase 3 LEVEL study and plans to initiate the LEVEL-2 study in 2025.
• High rates of study and therapy continuation during the blinded and open-label extension stages of the LEVEL study.

Negatives

• The net loss increased to $10.4 million for Q1 2025, compared to $3.8 million for Q1 2024.
• G&A expenses significantly increased to $5.7 million in Q1 2025, primarily due to increased compensation and professional fees.

Risks

• The company's clinical trials are subject to risks, including delays, costs, and results.
• Regulatory review and approval of product candidates may face delays.
• The company relies on third parties, including Orion Corporation and CROs.
• Volatility and uncertainty in the global economy and financial markets could impact the company.

Future Outlook

Tenax expects its cash and cash equivalents to fund the company through 2027. The company anticipates completing enrollment in the LEVEL study around the end of 2025 and sharing topline data in the middle of 2026. They also plan to commence the LEVEL-2 study in 2025.

Management Comments

• '2025 is off to a strong start. We continued to make meaningful progress in both the ongoing LEVEL study as well as preparations to commence our second registrational Phase 3 study, LEVEL-2,' said Chris Giordano, President and Chief Executive Officer of Tenax Therapeutics.
• Management believes levosimendan can control splanchnic blood volume and reduce blood flow to the left ventricle, potentially providing desirable effects for patients suffering from PH-HFpEF.
• Management aims to establish TNX-103 as a powerful therapeutic option for PH-HFpEF, a disease currently without any available treatments.

Industry Context

Tenax Therapeutics is focused on developing therapies for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), a prevalent condition with no approved treatments. The company's efforts to develop levosimendan (TNX-103) address a significant unmet medical need in the cardiopulmonary space.

Comparison to Industry Standards

• It is difficult to compare Tenax's results directly to industry standards due to the lack of approved therapies for PH-HFpEF.
• Other companies developing treatments for heart failure and pulmonary hypertension include Actelion Pharmaceuticals (acquired by Johnson & Johnson), Bayer, and Novartis, but their specific focus and approaches may differ.
• The success of Tenax's Phase 3 trials will be crucial in determining its competitive position in the market.

Stakeholder Impact

• Positive impact on patients with PH-HFpEF if TNX-103 proves to be an effective treatment.
• Shareholders may be impacted by the company's financial performance and clinical trial results.
• Employees are affected by the company's growth and development activities.

Next Steps

• Complete patient enrollment in the Phase 3 LEVEL study around the end of 2025.
• Initiate the second Phase 3 study, LEVEL-2, in 2025.
• Share topline data from the LEVEL study in the middle of 2026.

Key Dates

Keywords

TNX-103, Levosimendan, PH-HFpEF, Phase 3, Clinical Trial, Tenax Therapeutics, Financial Results